Antibiotics should not be used in Covid cases unless there is clinical suspicion of bacterial infection, according to a revised guideline for the treatment of adult coronavirus patients issued by the Centre.
The revised guidelines, issued on Sunday amid an uptick in coronavirus cases, stated that drugs such as Lopinavir-ritonavir, hydroxychloroquine, Ivermectin, Molnupiravir, Favipiravir, Azithromycin and Doxycycline should not be used for the treatment of adult COVID-19 patients in India.
The AIIMS/ICMR-COVID-19 National Task Force met on January 5 to revise the clinical guidance protocol. It has also advised doctors not to use convalescent plasma therapy.
"Antibiotics should not be used unless there is clinical suspicion of bacterial infection. Possibility of co-infection of COVID-19 with other endemic infections must be considered," the guidelines said.
Additionally, in moderate or severe diseases at high risk of progression, Remdesivir may be considered for up to five days. It should be started within 10 days of onset of symptoms in those having moderate to severe disease with a high risk of progression (requiring supplemental oxygen) but who are not on IMV or ECMO.
There is no evidence of benefit for the treatment of more than five days and is not to be used in patients who are not on oxygen support or in home setting, the guidelines stated. Besides, in rapidly progressing moderate or severe disease, Tocilizumab should be considered preferably within 24-48 hours of the onset of severe disease/ICU admission.
India saw a single-day rise of over 1,000 fresh COVID-19 cases on Sunday after 129 days. On Monday, the country reported a single-day rise of 918 cases while the active caseload has increased to 6,350.